Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01901185 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 77
- Enrollment target
NCT01901185 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 77 participants.
The verdict
NCT01901185, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 77 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the ability of people with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) to use an experimental autoinjector to self inject etanercept (Enbrel®).
Interventions
- DRUG Etanercept / Autoinjector A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2013-06-11 |
| Est. Completion | 2013-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01901185
The ClinicalTrials.gov registry entry for NCT01901185 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Etanercept / Autoinjector A is the first listed.
NCT01901185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01901185 about?
NCT01901185 is a clinical study titled "Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept". The purpose of this study is to assess the ability of people with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) to use an experimental autoinjector to self inject etanercept (Enbrel®).
What is the current status of trial NCT01901185?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 77 participants. The study started on 2013-06-11. Estimated completion is 2013-12-30.
What interventions are being tested in trial NCT01901185?
The interventions under investigation include: Etanercept / Autoinjector A (DRUG).
Who is sponsoring clinical trial NCT01901185?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.